

ID: Dr. Willemse
 Sex: F
 Birthdate: 10/12/1936


Exam Date: 7/15/2022
 Exam Description: External Patient: OCT



deepeye® TPS - nAMD Therapy Planning Support

Laterality: OD (R)

Prediction and Progression of Current Disease Activity:




High

Probably high


Probably low

Low

Interpretation: **High**: prediction of high disease activity (50-100%) | **Low**: prediction of low disease activity (49-0%)




Foveal B-Scan (49 of 97)



Foveal Segmented B-Scan (49 of 97)

- █ IRF - Intraretinal Fluid
- █ SRF - Subretinal Fluid
- █ PED - Pigment Epithelial Detachment

Prediction and progression of Long-Term Treatment Need (next 12 months):



High

Probably high

Probably low

Low

Interpretation:

High: prediction to receive more than 6 anti-VEGF therapy injections (50-100%)

Low: prediction to receive 6 or less anti-VEGF therapy injections (49-0%)

⚠ The AI analysis **does not replace the expert judgement of a qualified doctor**. Please observe the restrictions in the instructions for use (www.deepeye-medical.com/eifu) as well as the opinion of your local ophthalmological society for any treatment decision.

From the statement of the professional associations DOG, RG and BVA:

After initial therapy (upload), treatment strategy with intravitreal injections at least 4 weeks apart (brolucizumab at least 8 weeks):

- If there is **high disease activity**, treatment for PRN (pro re nata) or shortening of the interval by 2 to 4 weeks for T&E (treat & extend).
- If there is **no activity**, treatment can be suspended (PRN) or the interval can be extended by 2 to 4 weeks (T&E), provided that funduscopy and visual acuity do not contradict this.

note



(01) 4262449580017
 (8012) v1.3.0




deepeye Medical GmbH
 Paul-Heyse-Str. 2-4,
 80366 Munich, Germany
www.deepeye-medical.com


Job-ID 6877663aa3ae83994169278c
 Date & time: 2025-07-16 10:44:50

ID: Dr. Willemse
 Sex: F
 Birthdate: 10/12/1936



Exam Date: 7/15/2022
 Exam Description: External Patient: OCT




B-Scan: 43 of 97




B-Scan with most SRF: 43 of 97



B-Scan: 40 of 97



B-Scan with most PED: 40 of 97



Summary of the AI report (this is **not a medical report**, just merely a summary of the AI results).

- The OCT of the patient shows **high** disease activity in the **right eye** on **15.07.2022**.
- Most subretinal fluid was seen in B-Scan **43** of 97. Highest PED in B-Scan **40**.
- The long-term prognosis shows a trend towards **high** disease activity.

For instructions for use please visit: www.deepeye-medical.com/eifu

Notice: In case of any incidents (in relation with the medical device), please contact the local competent authority and/or the manufacturer: feedback@deepeye-medical.com.



(01) 4262449580017
 (8012) v1.3.0



deepeye Medical GmbH
 Paul-Heyse-Str. 2-4,
 80366 Munich, Germany
www.deepeye-medical.com

Job-ID 6877663aa3ae83994169278c
 Date & time: 2025-07-16 10:44:50